Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02298270
Other study ID # 2013P002605a
Secondary ID
Status Completed
Phase N/A
First received November 17, 2014
Last updated June 21, 2016
Start date March 2014
Est. completion date July 2015

Study information

Verified date June 2016
Source Massachusetts General Hospital
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

This study tests the efficacy of an 8-week, Skype-based, group resiliency training intervention (The Relaxation Response Resiliency Program) for improving psychological stress in patients with Neurofibromatosis. A control group will receive a general health education curriculum. The investigators hypothesize that patients will improve on measures of psychological stress as a result of the resiliency program.

A substudy (Unique Protocol ID: 2013P002605b) has been approved to test this study on a sub-population: patients with NF2 who are hard of hearing.


Recruitment information / eligibility

Status Completed
Enrollment 65
Est. completion date July 2015
Est. primary completion date July 2015
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Age 18 or older

2. Can read and speak English at or above the 6th grade level

3. Diagnosis of neurofibromatosis type 1, neurofibromatosis type 2, or schwannomatosis

Exclusion Criteria:

1. Severe active or untreated major mental illness that would interfere with study participation, to be determined at the discretion of the study investigator (e.g. untreated psychosis or suicidality)

2. Recent (within past 3 months) change in antidepressant medication

3. Use of formal relaxation training (including past participation in a mind-body program), currently or in the past 6 months.

4. Unable or unwilling to sign the informed consent documents

5. Unable or unwilling to complete psychological assessments online via the REDCap system.

6. Unable or unwilling to participate in an intervention delivered via videoconferencing with Skype.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care


Intervention

Behavioral:
The Relaxation Response Resiliency Program (3RP) via Skype
8-week group intervention, delivered via Skype, teaching relaxation and psychological resiliency enhancing skills. Topics include the relaxation response, meditation, and yoga.

Locations

Country Name City State
United States Massachusetts General Hospital Boston Massachusetts

Sponsors (2)

Lead Sponsor Collaborator
Massachusetts General Hospital The Children's Tumor Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Satisfaction with Life (SWL) The Satisfaction with Life (SWL) scale is a reliable and valid 5-item self-report measure of global life satisfaction. Responses are made on a 7-point scale with higher scores reflecting higher life satisfaction. Change between Baseline (week 0), Post-intervention (week 8) and Follow Up (week 32) No
Primary Quality of Life (WHOQOL-BREF) The WHOQOL-BREF comprises of 26 items which measure the following broad domains: physical health, psychological health, social relationships, and environment. The WHOQOL-BREF is a shorter version of the original instrument that may be more convenient for use in large research studies or clinical trials. Change between Baseline (week 0), Post-intervention (week 8) and Follow Up (week 32) No
Secondary Perceived Stress Scale (PSS-10) The PSS is a widely used psychological instrument for the measurement of the perception of stress. This 10-itam scale is designed to measure the degree to which situations in one's life are appraised, or considered stressful. The scores range from 0-40, with a higher score indicating higher perceived stress. Items were designed to detect how unpredictable, uncontrollable and overloaded respondents find their lives. Change between Baseline (week 0), Post-intervention (week 8) and Follow Up (week 32) No
Secondary The Pain Catastrophizing Scale (PCS) The Pain Catastrophizing Scale (PCS) is widely used to assess cognitive and affective responses to pain and to evaluate pain management program outcomes. Change between Baseline (week 0), Post-intervention (week 8) and Follow Up (week 32) No
Secondary Pain Numerical Rating Scale (Pain NRS) The Pain NRS is a scale for patient self-reporting measurements of pain. The measure was depicted by REINS as a standard measure to use in Neurofibromatosis clinical trials. Change between Baseline (week 0), Post-intervention (week 8) and Follow Up (week 32) No
Secondary Patient Health Quesionnaire (PHQ) The PHQ measures symptoms of depression and functional impairment. Change between Baseline (week 0), Post-intervention (week 8) and Follow Up (week 32) No
Secondary Brief Pain Inventory (BPI) The Brief Pain Inventory (BPI) allows patients to rate the severity of their pain (BPI-S) and the degree to which their pain interferes with common dimensions of feeling and function (BPI-I). Change between Baseline (week 0), Post-intervention (week 8) and Follow Up (week 32) No
Secondary Cognitive and Affective Mindfulness Scale (CAMS) The CAMS measures the degree to which individuals experience their thoughts and feelings. Change between Baseline (week 0), Post-intervention (week 8) and Follow Up (week 32) No
Secondary Posttraumatic Growth Inventory (PGI) The PGI is an instrument for assessing positive outcomes reported by persons who have experienced traumatic events. Change between Baseline (week 0), Post-intervention (week 8) and Follow Up (week 32) No
Secondary Interpersonal Reactivity Index (IRI) The IRI assesses the cognitive and affective dimensions of empathy. Change between Baseline (week 0), Post-intervention (week 8) and Follow Up (week 32) No
Secondary Distress Analogue Scales The Distress Analogue Scales measure participants' levels of stress, coping, distress, and discomfort. Change between Baseline (week 0), Post-intervention (week 8) and Follow Up (week 32). Also administered at mid-interevention, before each group session. No
Secondary Epworth Sleepiness Scale (ESS) The Epworth Sleepiness Scale (ESS) has been widely used to assess a person's average level of daytime sleepiness in daily life. Change between Baseline (week 0), Post-intervention (week 8) and Follow Up (week 32) No
Secondary Measure of Current Status (MOCS-A) The MOCS-A is a 13-item measure assessing participants' current self-perceived status on several skills such as: the ability to relax at will, recognize stress-inducing situations, restructure maladaptive thoughts, be assertive about needs, and choose appropriate coping responses as needed. Responses are made on a 7-point scale with higher scores reflecting higher life satisfaction. Change between Baseline (week 0), Post-intervention (week 8) and Follow Up (week 32) No
Secondary Life Orientation Test (LOT) Optimism Scale The LOT Optimism Scale measures individual differences in generalized optimism versus pessimism. Change between Baseline (week 0), Post-intervention (week 8) and Follow Up (week 32) No
Secondary The Gratitude Questionnaire (GQ-6) The GQ-6 revised is a 6-item measure that assesses individual differences in the proneness to experience gratitude in daily life. Scores range from 6-42, with a higher score indicating a greater sense of gratitude. Change between Baseline (week 0), Post-intervention (week 8) and Follow Up (week 32) No
Secondary Functional Assessment of Chronic Illness Therapy- Fatigue Scale (FACIT-Fatigue) The FACIT-Fatigue measures participants' tiredness, weakness, and difficulty conducting usual activities due to fatigue. Change between Baseline (week 0), Post-intervention (week 8) and Follow Up (week 32) No
Secondary Functional Assessment of Chronic Illness Therapy- Spirituality Scale (FACIT-Sp) The FACIT-Sp measures participants' spiritual well-being (sense of meaning in life and the sense of strength in one's faith) over the past 7 days. Change between Baseline (week 0), Post-intervention (week 8) and Follow Up (week 32) No
Secondary Medical Outcomes Study (MOS) Social Support Survey The MOS Social Support Survey measures various dimensions of social support. Change between Baseline (week 0), Post-intervention (week 8) and Follow Up (week 32) No
Secondary The 14-Item Resiliency Scale (RS-14) The RS-14 measures stress coping ability in the face of adversity. Change between Baseline (week 0), Post-intervention (week 8) and Follow Up (week 32) No
See also
  Status Clinical Trial Phase
Completed NCT03617276 - Reliability of Functional Outcome Measures in Neurofibromatosis 2
Active, not recruiting NCT00973739 - Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Phase 2
Completed NCT00030043 - An Implant for Hearing Loss Due to Removal of Neurofibromatosis 2 Tumors Phase 1
Recruiting NCT05685836 - 89Zr-Bevacizumab PET/CT Imaging in NF2 Patients
Completed NCT00004437 - Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2 Phase 2
Recruiting NCT03406208 - Resiliency Training for Adults With Neurofibromatosis Via Live Videoconferencing N/A
Suspended NCT03095248 - Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors Phase 2
Recruiting NCT01885767 - Neurofibromatosis (NF) Registry Portal
Completed NCT00863122 - Concentration and Activity of Lapatinib in Vestibular Schwannomas Early Phase 1
Recruiting NCT03079999 - Study of Aspirin in Patients With Vestibular Schwannoma Phase 2
Terminated NCT00911248 - PTC299 for Treatment of Neurofibromatosis Type 2 Phase 2
Completed NCT02811718 - Resiliency Training for Patients With NF2 Via Videoconferencing With Skype N/A
Enrolling by invitation NCT04890132 - Vestibular Precision: Physiology & Pathophysiology N/A
Completed NCT01490476 - Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients Phase 2
Active, not recruiting NCT00004483 - NF2 Natural History Consortium N/A
Recruiting NCT03893643 - Cutaneous and Mucosal Manifestations of Neurofribromatosis Type 2 in Children Under 15
Active, not recruiting NCT04283669 - Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas Phase 2
Completed NCT02831257 - AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas Phase 2